These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 36532066)

  • 1. Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy.
    Xu T; Liu Z; Huang L; Jing J; Liu X
    Front Immunol; 2022; 13():1057850. PubMed ID: 36532066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the immune microenvironment for ovarian cancer therapy.
    Blanc-Durand F; Clemence Wei Xian L; Tan DSP
    Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
    Zhu X; Lang J
    J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities.
    Garlisi B; Lauks S; Aitken C; Ogilvie LM; Lockington C; Petrik D; Eichhorn JS; Petrik J
    Curr Oncol; 2024 Jul; 31(7):3826-3844. PubMed ID: 39057155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction.
    Zhao M; Li J; Liu J; Xu M; Ji H; Wu S; Chen D; Hu H
    J Control Release; 2021 Jul; 335():320-332. PubMed ID: 34062192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment.
    Kang Y; Flores L; Ngai HW; Cornejo YR; Haber T; McDonald M; Moreira DF; Gonzaga JM; Abidi W; Zhang Y; Hammad M; Kortylewski M; Aboody KS; Berlin JM
    Bioconjug Chem; 2021 Aug; 32(8):1581-1592. PubMed ID: 34289694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
    Zang X; Song J; Yi X; Piyu J
    J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine Strategies for Heating "Cold" Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC.
    Yang Y; Zhao T; Chen Q; Li Y; Xiao Z; Xiang Y; Wang B; Qiu Y; Tu S; Jiang Y; Nan Y; Huang Q; Ai K
    Adv Sci (Weinh); 2022 Oct; 9(28):e2202797. PubMed ID: 35869032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered Nanomaterials for Tumor Immune Microenvironment Modulation in Cancer Immunotherapy.
    Xing H; Li X
    Chemistry; 2024 Jun; 30(32):e202400425. PubMed ID: 38576219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study.
    Gao Y; Chen L; Cai G; Xiong X; Wu Y; Ma D; Li SC; Gao Q
    Oncoimmunology; 2020; 9(1):1760067. PubMed ID: 32391193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrogel/nanoparticles-mediated cooperative combination of antiangiogenesis and immunotherapy.
    Yang A; Sheng S; Bai Y; Xing G; Yu X; Zhu D; Mei L; Dong X; Lv F
    Acta Biomater; 2022 Nov; 153():124-138. PubMed ID: 36179979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment.
    Li J; Zhao M; Sun M; Wu S; Zhang H; Dai Y; Wang D
    ACS Appl Mater Interfaces; 2020 Nov; 12(45):50734-50747. PubMed ID: 33124808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
    Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE
    Front Immunol; 2019; 10():1782. PubMed ID: 31456796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metal-organic framework-mediated multifunctional nanoparticles for combined chemo-photothermal therapy and enhanced immunotherapy against colorectal cancer.
    Liu H; Xu C; Meng M; Li S; Sheng S; Zhang S; Ni W; Tian H; Wang Q
    Acta Biomater; 2022 May; 144():132-141. PubMed ID: 35307591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smart Nanoparticle-Based Platforms for Regulating Tumor Microenvironment and Cancer Immunotherapy.
    Cheng R; Santos HA
    Adv Healthc Mater; 2023 Mar; 12(8):e2202063. PubMed ID: 36479842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
    Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
    Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination of NIR therapy and regulatory T cell modulation using layer-by-layer hybrid nanoparticles for effective cancer photoimmunotherapy.
    Ou W; Jiang L; Thapa RK; Soe ZC; Poudel K; Chang JH; Ku SK; Choi HG; Yong CS; Kim JO
    Theranostics; 2018; 8(17):4574-4590. PubMed ID: 30279723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifaceted therapeutic targeting of ovarian peritoneal carcinomatosis through virus-induced immunomodulation.
    Gujar S; Dielschneider R; Clements D; Helson E; Shmulevitz M; Marcato P; Pan D; Pan LZ; Ahn DG; Alawadhi A; Lee PW
    Mol Ther; 2013 Feb; 21(2):338-47. PubMed ID: 23299799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in understanding the immune microenvironment in ovarian cancer.
    Chen J; Yang L; Ma Y; Zhang Y
    Front Immunol; 2024; 15():1412328. PubMed ID: 38903506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy.
    Wang ZB; Zhang X; Fang C; Liu XT; Liao QJ; Wu N; Wang J
    Immunology; 2024 Sep; 173(1):14-32. PubMed ID: 38618976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.